Lintide

Lintide works through the amylin signaling pathway rather than the GLP-1 receptor pathway, representing a mechanistically distinct approach to pharmacological weight loss. Amylin is described as a 'second fullness signal' that the body naturally produces in response to food intake. This differentiates lintide from semaglutide and tirzepatide, which act on GLP-1 (and GIP) receptors. No specific dosage or dosing frequency is mentioned in the transcript.

Lintide, a novel amylin-based peptide developed by Eli Lilly, demonstrated approximately 20% body weight loss at its top dose over a 48-week clinical trial. This positions it in the same efficacy range as leading GLP-1 receptor agonists such as tirzepatide. The mechanism is distinct from GLP-1 agonism, instead targeting amylin — a satiety hormone naturally released during eating. The speaker notes the compound is still in trials and not yet available for clinical use.

The speaker flags a clinical caution that lintide remains investigational and not approved for general use. A specific concern is raised that doses studied in clinical trials frequently do not correspond to the doses individuals self-administer in real-world or off-label contexts. This is presented as a practical warning for patients or practitioners considering or anticipating use of the compound. No specific safe vs. unsafe dose thresholds are provided.